EPO and essential thrombocythemia: JAK2V617F mutation can drive PV, ET and PMF through constitutive activation of the receptors for erythropoietin (EPO-R), thrombopoietin (MPL) and granulocyte-colony stimulating factor (G-CSF-R) [10].